SCHEMBL4652941

SCHEMBL4652941

[O]C(=O)c1ccccc1C([O])=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.56
ALOX15 P16050 2/20 0.56
TSHR P16473 4/20 0.46
KDM4E B2RXH2 4/20 0.46
CES2 O00748 3/20 0.46
CES1 P23141 3/20 0.46
HPGD P15428 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
NAPRT Q6XQN6 2/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
HMGB1 P09429 1/20 0.46
CA4 P22748 1/20 0.46
CA6 P23280 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
MAPT P10636 3/20 0.43
HDAC8 Q9BY41 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL596041 0.88 ALDH1A1 (0.78) ALDH1A1ALOX15KDM4EHPGDSMN1; SMN2
SCHEMBL11586104 0.86 ALDH1A1 (0.58) ALDH1A1ALOX15TSHRKDM4EHPGD
SCHEMBL409296 0.82 KDM4E (0.64) ALDH1A1ALOX15TSHRKDM4EHPGD
SCHEMBL9856654 0.82 ALDH1A1 (0.46) ALDH1A1ALOX15TSHRKDM4ECES2
SCHEMBL891523 0.82 AKR1C3 (0.71) ALDH1A1KDM4ESMN1; SMN2MAPTHSD17B10
SCHEMBL6972335 0.80 TSHR (0.63) ALDH1A1ALOX15TSHRKDM4ECA1
SCHEMBL4166060 0.80 CES2 (0.64) ALDH1A1ALOX15TSHRCES2CES1
SCHEMBL16470694 0.80 ELANE (0.41) ALDH1A1ALOX15TSHRKDM4ESMN1; SMN2
SCHEMBL3806095 0.80 MAPT (0.58) ALDH1A1ALOX15TSHRKDM4EHPGD
SCHEMBL2165280 0.80 MEN1 (0.52) ALDH1A1ALOX15TSHRKDM4ECES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2669342-B1 ACTIVE-ENERGY-RAY-CURABLE INKJET INK COMPOSITION, ACTIVE-ENERGY-RAY-CURABLE INKJET INK, AND INKJET RECORDING METHOD KONICA MINOLTA INC (JP) 2020-03-18 EP disclosed
EP-2584011-B1 INKJET INK AND INKJET IMAGE FORMATION METHOD USING SAME KONICA MINOLTA HOLDINGS INC (JP) 2018-06-20 EP disclosed
US-9416289-B2 Active-energy-ray-curable inkjet ink composition, active-energy-ray-curable inkjet ink, and inkjet recording method Konica Minolta, Inc. (JP) 2016-08-16 US disclosed
US-9175180-B2 Inkjet ink and inkjet image formation method using same Konica Minolta, Inc. (JP) 2015-11-03 US disclosed
EP-2669342-A1 ACTIVE-ENERGY-RAY-CURABLE INKJET INK COMPOSITION, ACTIVE-ENERGY-RAY-CURABLE INKJET INK, AND INKJET RECORDING METHOD Konica Minolta, Inc. (JP) 2013-12-04 EP disclosed
US-20130307913-A1 ACTIVE-ENERGY-RAY-CURABLE INKJET INK COMPOSITION, ACTIVE-ENERGY-RAY-CURABLE INKJET INK, AND INKJET RECORDING METHOD Konica Minolta, Inc. (JP) 2013-11-21 US disclosed
EP-2584011-A1 INKJET INK AND INKJET IMAGE FORMATION METHOD USING SAME Konica Minolta Holdings, Inc. (JP) 2013-04-24 EP disclosed
US-20130095236-A1 INKJET INK AND INKJET IMAGE FORMATION METHOD USING SAME KONICA MINOLTA HOLDINGS, INC. (JP) 2013-04-18 US disclosed
EP-1652834-B1 Process for producing salicylic esters KAO CORP (JP) 2008-10-01 EP disclosed
EP-1652834-A1 Process for producing salicylic esters KAO CORPORATION (JP) 2006-05-03 EP disclosed
US-20060058547-A1 Process for producing salicylic esters KAO CORPORATION (JP) 2006-03-16 US disclosed
EP-1634571-A1 Transesterification process for producing salicylic esters used in perfumes KAO CORPORATION (JP) 2006-03-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058547-A1 Process for producing salicylic esters NOTUM, FASN, AGPS ALDH1A1 268/4885ALOX15 23/4885TSHR 3808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.